EE05439B1 - Ketotifeeni sisaldav oftalmiline ravimkoostis - Google Patents

Ketotifeeni sisaldav oftalmiline ravimkoostis

Info

Publication number
EE05439B1
EE05439B1 EEP200200040A EEP200200040A EE05439B1 EE 05439 B1 EE05439 B1 EE 05439B1 EE P200200040 A EEP200200040 A EE P200200040A EE P200200040 A EEP200200040 A EE P200200040A EE 05439 B1 EE05439 B1 EE 05439B1
Authority
EE
Estonia
Prior art keywords
pharmaceutical composition
composition containing
ophthalmic pharmaceutical
containing ketotifen
ketotifen
Prior art date
Application number
EEP200200040A
Other languages
English (en)
Estonian (et)
Inventor
Johanna Adam Marcia
Fetz Andrea
Lajos Kis Gy�rgy
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of EE200200040A publication Critical patent/EE200200040A/xx
Publication of EE05439B1 publication Critical patent/EE05439B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EEP200200040A 1999-07-23 2000-07-21 Ketotifeeni sisaldav oftalmiline ravimkoostis EE05439B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99114508 1999-07-23
PCT/EP2000/007030 WO2001007049A2 (fr) 1999-07-23 2000-07-21 Composition ophthalmique

Publications (2)

Publication Number Publication Date
EE200200040A EE200200040A (et) 2003-04-15
EE05439B1 true EE05439B1 (et) 2011-08-15

Family

ID=8238654

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200040A EE05439B1 (et) 1999-07-23 2000-07-21 Ketotifeeni sisaldav oftalmiline ravimkoostis

Country Status (20)

Country Link
US (2) US6777429B1 (fr)
EP (1) EP1198223A2 (fr)
JP (1) JP2003505419A (fr)
KR (1) KR20020012261A (fr)
CN (1) CN1358086A (fr)
BR (2) BR0012696A (fr)
CA (1) CA2377024A1 (fr)
CZ (1) CZ300614B6 (fr)
EE (1) EE05439B1 (fr)
HK (1) HK1046631A1 (fr)
HU (1) HU230738B1 (fr)
IL (1) IL146973A0 (fr)
MX (1) MXPA02000849A (fr)
NO (1) NO331228B1 (fr)
NZ (1) NZ516108A (fr)
PL (1) PL202496B1 (fr)
RU (1) RU2248789C2 (fr)
UA (1) UA74788C2 (fr)
WO (1) WO2001007049A2 (fr)
ZA (1) ZA200200425B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100436A2 (fr) * 2001-06-08 2002-12-19 Novartis Ag Compositions pharmaceutiques
AR034372A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
AR034371A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
ES2534904T3 (es) * 2003-01-22 2015-04-30 Senju Pharmaceutical Co., Ltd. Preparación de absorción percutánea para el tratamiento de enfermedad oftálmica, uso del mismo y método para la migración del remedio oftálmico en el tejido tópico en los ojos
US20070208058A1 (en) * 2004-10-25 2007-09-06 Bryant Roy W Stable Pharmaceutical Compositions and Methods of Making and Using Same
DE602005020513D1 (de) * 2004-10-25 2010-05-20 Bausch & Lomb Ophthalmische zusammensetzungen und verfahren zu deren verwendung
US20060089384A1 (en) * 2004-10-25 2006-04-27 Minno George E Ophthalmic compositions and methods of using the same
US20070048389A1 (en) * 2005-08-26 2007-03-01 Fu-Pao Tsao Stabilized and preserved ketotifen ophthalmic compositions
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
ES2406764T3 (es) 2006-06-16 2013-06-10 Regeneron Pharmaceuticals, Inc. Formulaciones que comprenden antagonistas de VEGF para administración intravítrea
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
BRPI0718374A2 (pt) * 2006-09-29 2013-06-25 Johnson & Johnson Vision Care mÉtodos e dispositivos oftÁlmicos usados no tratamento de alergias oculares
WO2008153761A1 (fr) * 2007-05-23 2008-12-18 Mastcell Pharmaceuticals, Inc. Méthodes
US8445435B2 (en) * 2007-09-28 2013-05-21 The Brigham And Women's Hospital, Inc. Mast cell stabilizers in the treatment of obesity
WO2009142772A2 (fr) 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Méthodes et traitement d’allergies et inflammations associées à des pathologies gastro-intestinales
US20100240624A1 (en) * 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic Formulations of Ketotifen and Methods of Use
RU2549472C1 (ru) * 2013-12-26 2015-04-27 Илья Александрович Марков Фармацевтическая композиция в форме капель для профилактики и лечения аллергических заболеваний глаз
CA3007276C (fr) 2015-12-03 2021-12-28 Regeneron Pharmaceuticals, Inc. Utilisation de l'inhibiteur de vegf pour traiter la degenerescence maculaire dans une population de patients
CN111450051B (zh) * 2020-04-21 2022-03-18 武汉贝参药业股份有限公司 一种富马酸酮替芬口服溶液的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62277323A (ja) 1986-02-19 1987-12-02 Sankyo Co Ltd フマル酸ケトチフエン含有点眼液の製法
JPH07324034A (ja) * 1994-05-30 1995-12-12 Toa Yakuhin Kk フマル酸ケトチフェン含有の点眼剤
JPH11189533A (ja) * 1997-12-25 1999-07-13 Taisho Pharmaceut Co Ltd 点眼薬
EP0938896A1 (fr) 1998-01-15 1999-09-01 Novartis AG Compositions pharmaceutiques autoclavables contenant des agents de chelation

Also Published As

Publication number Publication date
BRPI0017528B1 (pt) 2017-06-13
NO331228B1 (no) 2011-11-07
CA2377024A1 (fr) 2001-02-01
ZA200200425B (en) 2002-10-30
NO20020319L (no) 2002-01-21
NZ516108A (en) 2004-04-30
UA74788C2 (en) 2006-02-15
WO2001007049A2 (fr) 2001-02-01
NO20020319D0 (no) 2002-01-21
JP2003505419A (ja) 2003-02-12
IL146973A0 (en) 2002-08-14
PL202496B1 (pl) 2009-06-30
WO2001007049A3 (fr) 2001-03-29
CZ2002243A3 (cs) 2002-04-17
HK1046631A1 (zh) 2003-01-24
HUP0202243A2 (hu) 2002-12-28
BRPI0017528B8 (pt) 2021-05-25
CZ300614B6 (cs) 2009-07-01
CN1358086A (zh) 2002-07-10
HUP0202243A3 (en) 2006-03-28
US6774137B2 (en) 2004-08-10
BRPI0017528A2 (pt) 2010-01-19
EP1198223A2 (fr) 2002-04-24
KR20020012261A (ko) 2002-02-15
EE200200040A (et) 2003-04-15
MXPA02000849A (es) 2002-07-30
PL352382A1 (en) 2003-08-25
BR0012696A (pt) 2002-04-09
US20020183359A1 (en) 2002-12-05
US6777429B1 (en) 2004-08-17
HU230738B1 (hu) 2018-01-29
RU2248789C2 (ru) 2005-03-27

Similar Documents

Publication Publication Date Title
FI991485A (fi) Uusi farmaseuttinen koostumus
NO20015175D0 (no) Farmasöytisk sammensetning
DK1052974T3 (da) Farmaceutisk sammensætning indeholdende epothilon
PT1242087E (pt) Composicoes farmaceuticas
EE05439B1 (et) Ketotifeeni sisaldav oftalmiline ravimkoostis
ID27415A (id) Komposisi farmaseutik
DE60011487D1 (de) Ophthalmisches Gerät
DE60037203D1 (de) Medikamentenspender
DE60011853D1 (de) Injektionsspritze
NO20012915L (no) Ny farmasöytisk formulering
NO20020086D0 (no) Smaksmaskerte farmasöytiske flytende formuleringer
DK1395242T3 (da) Flydende farmaceutisk sammensætning
ID29262A (id) Komposisi farmasi
PT1086701E (pt) Composicao laxante contendo simeticone
NO20022606L (no) Farmasöytiske kombinasjoner
NO20015510L (no) Medikament for lokal påföring
PT1239832E (pt) Composicoes farmaceuticas
NO20014926D0 (no) Farmasöytiske forbindelser
NO20003786D0 (no) Oftalmisk sammensetning
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
ID30032A (id) Formulasi farmasi
FI4488U1 (fi) Farmaseuttinen koostumus
ATE297187T1 (de) Resorcinenthaltende zusammensetzung
AR025867A1 (es) Formulacion portasdora farmaceutica
EE200100697A (et) Farmatseutiline kompleks